Alebund is a China-based clinical stage biopharmaceutical company dedicated to providing better clinical solutions to patients with kidney diseases and related chronic conditions.
Location: China, Shanghai
Employees: 51-200
Founded date: 2018
Investors 4
| Date | Name | Website |
| - | LAV | lavfund.co... |
| - | Octagon Ca... | octagoninv... |
| - | 3H Health ... | 3hhinvestm... |
| 02.11.2025 | SymBiosis | symbiosis.... |
Mentions in press and media 13
| Date | Title | Description |
| 08.09.2026 | Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy | SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that it has recently received cleara... |
| 26.08.2026 | Alebund Pharmaceuticals Announces 2026 Interim Results | SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated ... |
| 21.07.2026 | Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia | SHANGHAI, July 21, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the first participant has been ... |
| 29.06.2026 | Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board | Deepening Its Commitment to Kidney Disease and Accelerating Toward Becoming a Global Leader in Renal Innovation SHANGHAI, June 29, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"... |
| 06.05.2026 | Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia | SHANGHAI, May 6, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal... |
| 17.03.2026 | Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306 | AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, an... |
| 26.06.2025 | Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia | SHANGHAI, June 26, 2025 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic con... |
| 09.01.2025 | Funding Frenzy: A Surge in Innovative Ventures Across the Globe | The world of startups is a bustling marketplace, where ideas collide and fortunes are made. Recent funding rounds highlight a vibrant ecosystem, brimming with potential. From sustainable agriculture to cutting-edge healthcare, the landscape... |
| 08.01.2025 | Deals in brief: Xnergy and HiFeed secure funding, Anthropic nears completion of USD 2 billion round, China’s Weimai raises Series D funding, and more | Xnergy secures investment from Woori Venture Partners Xnergy, a Singapore-based company specializing in high-power wireless charging solutions, has received an undisclosed investment from South Korean venture capital firm Woori Venture Part... |
| 07.01.2025 | Alebund Pharmaceutical announced the 1st closing of RMB 550 million in Series C financing | SHANGHAI and YANGZHOU, China, Jan. 7, 2025 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and ... |
Show more